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Objectives: To evaluate the characteristics and outcomes of treatment of patients with pheochromocytoma at Inkosi Albert 
Luthuli Central Hospital (ILACH) in Durban, South Africa over 14 years.
Design: Retrospective chart review.
Setting and subjects: Patients with pheochromocytoma attending the endocrinology clinic at IALCH between 2012 and 2016 
were studied.
Outcome measures: Clinical, biochemical and radiological data were collected at presentation, on discharge, one  year and 
five years after surgical intervention; tumour characteristics, histopathological features and surgical outcome were also assessed.
Results: The analysis included 35 patients (mean age 33.2 ± 15.7 years; 60% female).
Headache (68.6%), palpitation (60%) and sweating (57.6%) were the three most common presenting symptoms; hypertension 
was the predominant clinical finding (85.7%). Most pheochromocytomas were sporadic (82.9%), adrenal gland tumours (68.6%) 
and benign (77.1%); of eight patients with malignant tumours, two were familial. Adrenalectomy was undertaken in the majority 
(n = 34; 97.1%); 55.2% were large tumours. The use of adjunctive radiotherapy (n = 4; 11.4%) and chemotherapy (n = 1; 2.9%) was 
low. There was low overall mortality (5.7%), but 57.6% developed intraoperative hypotension. At one year postoperatively, 80% 
(n = 28) of patients were defined as cure, biochemically in 23 (82.1%) and with radiology in five (17.9%).
Conclusions: Most patients presenting to IALCH had large intra-abdominal tumours with high cure rate, low mortality but a high 
rate of perioperative complications. Late presentation and large tumour size was a feature.
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Introduction
Pheochromocytomas are rare neuroendocrine tumours with 
variable clinical presentation including hypertension.1−4 These 
are benign or malignant catecholamine-producing tumours that 
arise from neural crest chromaffin cells, which are located in the 
adrenal medulla or extra- adrenal paraganglia. The majority are 
those arising from the adrenal medulla and are called 
pheochromocytomas (80–85%) while tumours arising outside 
the adrenal gland are referred to as extra-adrenal 
pheochromocytomas or catecholamine-secreting 
paragangliomas (15–20%). The only criterion for distinguishing 
malignant pheochromocytoma from benign lesions is the 
presence of metastases of chromaffin tissue at sites not usually 
present.1,2,4−10
Although it can be cured with surgery, when undiagnosed 
pheochromocytoma can be fatal.1 Therefore, early detection of 
pheochromocytoma is crucial to prevent the associated life-
threatening cardiovascular complications (cardiomyopathy, 
myocardial infarction, cardiac arrhythmia and stroke).1,2,6 The 
reported prevalence is 0.1–0.6% in hypertensive patients with an 
annual incidence of 2–8 cases per million.1,2,11,12 Age at 
presentation is typically in the third–fifth decades of life with a 
female preponderance.1,3
While most pheochromocytomas are sporadic, at least 30% of 
these tumours may be hereditary. The inherited familial 
syndromes associated with pheochromocytoma include 
multiple endocrine syndrome type 2 (MEN 2), von Hippel-Lindau 
(VHL) syndrome, neurofibromatosis type 1 (NF-1), and familial 
paraganglioma.1,2,10,11
The clinical features of pheochromocytomas are mainly due to 
the production of catecholamines, with the commonest 
symptoms being headache, palpitation and diaphoresis. 
However, because of the rarity of these tumours, it is not cost-
effective to screen all hypertensive patients; the recommendation 
is that only patients with a high index of suspicion, namely those 
with features of hyper-adrenergic spells, a familial syndrome and 
patients with adrenal incidentaloma be investigated.1,2,6,11,12
When the tumour is suspected clinically, biochemical 
confirmation (plasma and urinary catecholamines (adrenaline, 
noradrenaline)) and their metabolites (metanephrine and 
normetanephrine) is required followed by tumour localisation 
using various imaging studies.1−3,5,10−13 It is advised that plasma 
tests should be confined to patients with a high clinical suspicion 
to avoid a high rate of false-positive results.16 When compared 
with urinary-fractionated metanephrines, which have high 
sensitivity and specificity (91–98%), plasma-fractionated 
metanephrines have higher sensitivity (96–100%) but lower 
specificity (85–89%).1,2,11,17
Surgical resection followed by postoperative monitoring is the 
safest and the most effective therapeutic intervention for 
pheochromocytoma.1,2,4,9,11,14,18
Although there are several reports on pheochromocytoma from 
centres in developed countries,19−22 there is limited information 
available from developing regions of the world such as sub-
Saharan Africa. This is probably related to limited healthcare 
resources and laboratory facilities for the diagnosis of 
pheochromocytoma in Africa. Available reports from South 
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normetanephrine) is required followed by tumour localisation 
using various imaging studies.1−3,5,10−13 It is advised that plasma 
tests should be confined to patients with a high clinical suspicion 
to avoid a high rate of false-positive results.16 When compared 
with urinary-fractionated metanephrines, which have high 
sensitivity and specificity (91–98%), plasma-fractionated 
metanephrines have higher sensitivity (96–100%) but lower 
specificity (85–89%).1,2,11,17
Surgical resection followed by postoperative monitoring is the 
safest and the most effective therapeutic intervention for 
pheochromocytoma.1,2,4,9,11,14,18
Although there are several reports on pheochromocytoma from 
centres in developed countries,19−22 there is limited information 
available from developing regions of the world such as sub-
Saharan Africa. This is probably related to limited healthcare 
resources and laboratory facilities for the diagnosis of 
pheochromocytoma in Africa. Available reports from South 
 
Africa are limited to studies reported from a tertiary referral 
centre in Johannesburg. In 54 patients who presented with 
pheochromocytoma between 1980 and 2009, there was low 
mortality (7.4%; n = 4); > 90% of those patients who were 
diagnosed based on biochemical profile before the 
histopathological confirmation had a good outcome.23
To date there are no reports of the clinical presentation and 
outcome of patients with pheochromocytoma in Durban. This 
study was undertaken to determine the characteristics and 
outcome of pheochromocytoma patients who attended and 
were managed in the Endocrinology Clinic at Inkosi Albert 
Luthuli Central Hospital (IALCH) in Durban, South Africa.
Study design and methods
Study design
A retrospective chart review was undertaken on all patients with 
pheochromocytoma who were managed at the Endocrinology 
Clinic at Inkosi Albert Luthuli Central Hospital (IALCH) in Durban, 
South Africa between September 1, 2002 and December 31, 
2016. IALCH is a public tertiary referral teaching hospital with a 
total bed capacity of almost 900; this hospital provides specialist 
and subspecialist healthcare services for more than 10 million 
inhabitants in the province of KwaZulu-Natal and parts of the 
Eastern Cape Province. The study was approved by the Biomedical 
Research Ethics Committee of the University of KwaZulu-Natal 
(reference: BE307/13).
Study methods
Clinical information on all patients with pheochromocytoma was 
retrieved from hospital records; the hospital has a computerised 
data management system, which allows for record keeping and 
retrieval. For each patient, information at presentation, post-
surgery (at discharge, one year, five years and > 10 years, where 
applicable) was recorded. These included demographic details, 
clinical presentation, associated co-morbidities, physical 
examination, biochemical and genetic testing (where applicable), 
radiological, surgical and histological findings. No patients were 
excluded from the study over the study period.
Laboratory tests were undertaken by the Chemical Pathology 
Laboratory at IALCH or its referral laboratory. Pre- and post-
surgery hormonal assessment for pheochromocytoma: 24 h 
urine catecholamines (adrenaline, noradrenaline and dopamine) 
were available for all patients; serum chromogranin A has been 
measured routinely since 2009 and screening for MEN 
commenced routinely in 2007. Other routine biochemical and 
haematological tests (plasma glucose, urea and electrolytes, 
serum calcium, full blood count) were also available.
The biochemical criteria used for the diagnosis of 
pheochromocytoma was a 24 h urine catecholamine level  >  2 
times the upper limit of the normal reference range for the IALCH 
laboratory.2,16 The normal reference ranges for urine 
catecholamines at the IALCH laboratory are as follows: 24 h urine 
adrenaline 0–86  nmol/24 h; noradrenaline 0–615  nmol/24 h; 
dopamine 0–3786  nmol/24 h. The reference range for serum 
chromogranin A is 0–101.9  ng/ml. Urine catecholamines were 
measured with reverse phase high-pressure liquid 
chromatography (HPLC) (Recipe kit, Recipe, Munich, Germany); 
serum chromogranin A was measured with an automated 
immunofluorescent method (Thermo Fischer kit, Thermo Fischer 
Scientific, Henningsdorf, Germany).
Screening for MEN 2A included measurement of serum 
parathyroid hormone, calcitonin, 24 h urine free cortisol and 
thyroid ultrasound. Molecular genetic testing for other familial 
disorders was also done at the time of the diagnosis, where these 
were considered. In addition, serum calcium and random blood 
glucose levels were done for all patients preoperatively.
Radiological investigations were performed to determine 
tumour location (whether adrenal or extra-adrenal and unilateral 
or bilateral lesion), tumour size, evidence of metastasis and 
associated calcification, necrosis and or haemorrhage. These 
included ultrasonography, computerided tomography (CT) scan, 
magnetic resonance imaging (MRI), I123metaiodobenzylguanidine 
scintigraphy (MIBG) and positron emission tomogram (PET) 
scan. Malignant pheochromocytoma was considered if lesions 
were found in other organs. Most patients had preoperative and 
multiple postoperative CT scans. Postoperatively all the CT 
reports were reviewed for the presence of residual tumour and/
or evidence of local or metastatic tumour recurrence.
Cure was defined biochemically in secretory tumours and these 
include all tumours in whom the preoperative levels were in the 
diagnostic range (> 2 x ULN) as well as any elevation above the 
normal range. In this study, only normal 24 h urine catecholamines 
were used to define biochemical cure; chromogranin A was not 
used as a biochemical criterion as it was not routinely measured 
until 2009 and because of lack of concordance with urine 
catecholamines in cured patients. In patients with non-secretory 
(non-functional) tumours, cure was determined radiologically by 
absence of tumour on radiological imaging post-surgery.
Follow-up was undertaken by the Endocrinology Clinic for all 
patients and included clinical examination, repeat imaging and 
hormonal testing.
Statistical analysis
Statistical analysis was performed using STATA† (V13.1; STATA/IC, 
College Station, TX, USA). Descriptive statistics were used for 
demographic and clinical data. Frequencies and percentages 
were used for categorical data. As numerical data did not meet 
the assumption of normality using the Shapiro–Wilk test, 
medians and interquartile ranges (IQR) were reported. Subgroup 
comparisons for categorical variables were compared with 
Fisher’s exact test due to the small cell sizes and the two-sample 
Wilcoxon rank-sum (Mann–Whitney) test was used for continuous 
variables. A p-value < 0.05 was considered statistically significant. 
Results
Patient characteristics based on age, gender and 
race
A total of 35 patients (M:F; 14:21), with suspected 
pheochromocytoma were reviewed between 2002 and 2016. 
Mean age at presentation was 33.2 ± 15.7 years (age range 11–
69  years). Seven patients presented during childhood (< 
18  years). In all patients, the diagnosis of pheochromocytoma 
was made ante-mortem. The majority (60%; n = 21) were African 
(black) and 28.6% (n = 10) were Asian Indians; Whites (8.6%; n = 
3) and mixed-race (Coloured) (2.9%; n = 1) patients constituted 
the remainder (Table 1).
Presenting clinical features
Figure 1 shows the clinical features at presentation. The three 
most common symptoms were headache (68.6%), palpitation 
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(60%), and sweating (57.6%). Abdominal pain, fatigue and 
weight loss were also frequent symptoms. The majority of 
patients (n = 30; 85.7%) presented with hypertension; of these, 
65.7% had sustained hypertension and 20% had paroxysmal 
hypertension. Clinical features of established hypertension, 
namely retinopathy (grade I (n = 4; 12.5%), grade II (n = 4; 12.5%) 
and grade III (n = 1; 3.1%)) and left ventricular hypertrophy were 
found in 28.1% and 34.3%, respectively. Orthostatic hypotension 
was a feature in seven (20%) patients. Three patients were 
pregnant at presentation; one in the second trimester and two in 
the third trimester.
Co-morbidities at presentation included diabetes mellitus (n = 3; 
8.6%) and chronic kidney disease (n = 2; 5.7%).
Tumour location and characteristics
All the patients presented with intra-abdominal tumours (Table 
2). Of these, 24 (68.6%) originated from the adrenal gland, 10 
(28.6%) were located extra-adrenally and one (2.9%) was a 
combined adrenal and extra-adrenal tumour. Of the 25 adrenal 
tumours, the majority (88%; n = 22) were unilateral and right-
sided (68.2%; n = 15) tumours; three (12%) were bilateral adrenal 
tumours. Of the 11 extra-adrenal tumours, three were located in 
the urinary bladder, seven in the lower abdomen and one in the 
Organ of Zuckerkandl.
Malignancy was diagnosed in eight (22.9%) patients (four 
adrenal; three extra-adrenal; one combined adrenal and extra-
adrenal) and 27 (77.1%) were considered benign tumours. 
Lymph node was the most common site of metastasis accounting 
for 62.5% (n = 5) of all malignant tumours; pulmonary and 
vascular (inferior vena cava and unspecified blood vessel 
invasion) metastasis was found in 25% (n = 2).
Table 1: Characteristics of patients with pheochromocytoma at 
presentation (n = 35)
Note: Data are expressed as mean ± SD or %.
Variable Available data (n) %
Male:female 14:21 40:60
Age (years) 35 33.2 ± 15.7
Ethnicity 35
 African 20 57.1
 Indian 11 31.4
 White 3 8.6
 Coloured (Mixed Race) 1 2.9
Weight (kg) 35 65.0 ± 17.9
Height (cm) 35 162.2 ± 11.3


































































Figure 1: Presenting clinical features in patients with pheochromocytoma (n = 35). ■ represents presenting symptoms and  represents clinical 
findings.
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Figure 1: Presenting clinical features in patients with pheochromocytoma (n = 35). ■ represents presenting symptoms and  represents clinical 
findings.
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142), noradrenaline 1445 (536–3384), dopamine 1319 (500–
2252); mean 24 h urine adrenaline (144.17  ±  268.20) was 1.7 
times and noradrenaline (3064.70  ±  3727.20) five times above 
the reference range. In the 25 patients in whom they were 
measured, median (IQR) serum chromogranin A was 739.4 
(218.5–1399) ng/ml; the mean value (1173.12  ±  1466.37) was 
11.5 times above the reference range. Mean serum calcium was 
2.40 ± 0.16 mmol/l and 23% (n = 8) had hypercalcemia. Median 
(IQR) for plasma glucose was 5.7 mmol/l (4.6–7.9); hyperglycaemia 
was found in 25.7% (n = 9) of these, three were diagnosed with 
diabetes mellitus prior to presentation.
Radiological tests
Radiological characteristics are given in Table 3. At presentation, 
the majority (n = 31; 88.6%) had CT scan for initial tumour 
localisation. Four patients (11.4%) had MRI scans (three subjects 
were pregnant and the indication for the MRI in the fourth patient 
was unclear); of these, one showed evidence of metastasis. In all 
(100%), CT or MRI (where applicable) scans correctly identified 
tumours before surgery. Baseline MIBG scans were done in 60% 
(n = 21); of these, 19 (90%) correctly identified the tumour 
preoperatively; two tumours that were not identified by MIBG 
scan were non-secretory. PET scans were performed in 25.7% (n = 
9) for identification of distant metastasis where results of CT or 
MIBG scans were inconclusive. Tumour necrosis and associated 
calcification or haemorrhage was recorded radiologically in five 
(14.3%) patients (four on CT scan and one on MIBG study).
Treatment modalities
Table 4 outlines the mode of therapy. The majority (n = 34; 97.1%) 
of patients had adrenal surgery as primary therapy. Anterior 
midline adrenalectomy was the most common surgical approach 
(n = 19; 54.3%) and laparoscopic adrenalectomy (n = 15; 42.9%) 
in the remainder.
Medical therapy (alpha-adrenergic blockers) alone was used only 
in one patient who refused surgery.
Other therapeutic modalities included MIBG-based radiotherapy 
for four (11.4%) patients (one each for massive tumour extension 
to IVC, distant metastasis to the lung, residual metastatic tumour 
and having local recurrent disease); chemotherapy was utilised 
in one (2.9%) subject who had metastatic disease.
Alpha-adrenergic blockers were the commonest preoperative 
anti-hypertensive medication used (n = 31; 88.6%), followed by 
calcium channel (n = 18; 51.4%) and beta-adrenergic blockers (n 
= 17; 48.6%).
Perioperative complications are presented in Table 4. Two patients 
(5.9%) died: one intraoperative with acute haemorrhagic shock 
and one on day four postoperatively, due to septic shock. Of the 
34 patients who were treated surgically, 22 (64.7%) experienced a 
complication. The most frequently documented intraoperative 
complication was hypotension (55.9%), followed by intraoperative 
haemorrhage (20.6%). At surgery, tumour size was recorded in 
most cases (n = 29; 82.9%) with all malignant and 21 benign 
tumours; the largest dimensions were recorded as ranging from 3 
cm to 12 cm (with mean 6.4 cm). Malignant tumours (mean size 
9 cm) were larger than benign (mean size 5.6 cm) tumours. Large 
tumour size (> 6 cm) was found in 55.2% (n = 16).
Tumour histology
All tumours were biopsied and histology confirmed adrenal 
pheochromocytoma in 68.6% (n = 24) and paraganglioma in 
The majority (n = 29; 82.9%) of patients had sporadic tumours. 
Only six (17.1%) patients had familial syndromes; of these, five 
had VHL (four of them from the same family: father, son and two 
daughters) and one had MEN type 2a based on the concomitant 
presence of biochemical (raised calcitonin level) and radiological 
features of medullary thyroid carcinoma on ultrasound and CT 
scan. Furthermore, five of the familial cases had adrenal tumours 
(one bilateral and four unilateral) and only one case was 
documented as extra-adrenal.
Of the 35 patients, 20 (57.1%) were diagnosed on the basis of 
biochemical results (i.e. > 2 times ULN of 24 h urine catecholamine) 
and the diagnosis in the remainder (n = 15; 42.9%) was incidental 
(either clinical and/or radiological) as they were non-functional 
(non-secretory) tumours or had mild elevation in 24 h urine 
catecholamine (i.e. less than twice ULN). Secretory tumours 
accounted for 77.1% (n = 27). Noradrenaline was the predominant 
(92.6%) catecholamine secreted; adrenaline (37%) and dopamine 
(11.1%) constituted the remainder.
Biochemical characteristics
In 34 patients in whom it was measured, median (IQR) 24 h urine 
catecholamine (nmol/24hr) was as follows: adrenaline 31 (12–
Table 2: Classification of pheochromocytoma in patients with 
pheochromocytoma (n = 35)
Note: *based on metastasis, †any value above the upper limit of normal.
Factor Available data (n) n %
Tumour type 35
 Benign 27 77.1
 Malignant ⃰ 8 22.9
Tumour location 35
 Adrenal only 24 68.6
 Benign 20 57.1
 Malignant ⃰ 4 11.4
 Extra-adrenal only 10 28.6
 Benign 7  20
 Malignant ⃰ 3  8.6
 Combined adrenal/extra-adrenal 1  2.9
 Benign 0  0.0
 Malignant ⃰ 1  2.9
Tumour secretory state 35
 Secretory (functional)† 27 77.1
 Biochemical type:
 Adrenaline only 0  0.0
 Noradrenaline only 16 59.3
 Adrenaline and noradrenaline 8 29.6
 Dopamine only 1  3.7
 Dopamine and adrenaline 1  3.7
 Dopamine and noradrenaline 0  0.0
 Dopamine, adrenaline and 
noradrenaline
1  3.7
 Non-secretory (non-functional) 7  20
 Unknown 1  2.9
Heredity status 35
 Sporadic 29 82.9
 Inherited (familial) 6 17.1
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Patient outcome on discharge, one year and five 
years post-surgery
Of the 35 patients in whom pheochromocytoma was confirmed 
histologically, 80% (n = 28) were defined as cured one year 
postoperatively. Of these, 23 (82.1%) had secretory tumours and 
deemed as cure by the biochemical definition; five (17.9%) 
patients with non-secretory tumours were deemed as cure 
radiologically. On the other hand, seven (20%) patients were 
deemed ‘not cured’; these included two patients at one year 
postoperatively, two at five years postoperatively, one who 
refused surgery and two who died within a week of surgery.
No significant difference was found for baseline biochemical and 
radiological features between cured and non-cured 
pheochromocytoma patients (Table 5).
Discussion
This study on characteristics and outcomes of treated patients 
with pheochromocytoma has shown that all tumours presented 
intra-abdominally, the majority located in the adrenal gland and 
most were benign tumours. Cure was documented in the 
majority and, despite the high rate of perioperative complications, 
the overall mortality was low. Clinical presentation in most 
patients included the classical pheochromocytoma triad 
associated with hypertension.
The pheochromocytoma triad (headache, 68.6%; palpitations, 
60%; and sweating, 57.6%) were the main presenting symptoms 
in the majority of patients, confirming the classical hyper-
adrenergic spells of the tumours. This is in keeping with the 
available literature, which reports headaches in 55–90%, 
palpitations in 50–77% and sweating in 40–74% of patients with 
pheochromocytoma.2,3,6,23
Hypertension was the most frequent presenting clinical finding, 
found in 85.7% in the current study, which is quite close to the 
figures (90–100%) from most available reports,2,3,6,23 except one 
study that reported a low rate (45%).19 Furthermore, in our study, 
sustained hypertension (65.7%) was more common than 
paroxysmal hypertension (20%), similar to studies from Asia and 
Europe,9,19,22 but higher than other studies, which report similar 
proportions for both types.3,6,23 Hypertension persisted in 33.3% 
after successful resection of the tumour (as defined biochemically 
and radiologically); similar findings have been reported from 
centres in Asia9,19 and Sweden,22 with rates of 10–35%. This may 
be related to the late presentation with target organ (renal) 
involvement from hypertension or the coexistence of essential 
hypertension in this study.
Pheochromocytoma in pregnancy can cause death for both 
mother and foetus with high mortality rate that can reach 50% in 
both.24 Only three patients (8.6%) in this study were diagnosed 
during pregnancy. However, as in the larger series from 
Johannesburg,23 there was no maternal mortality in this study 
and this is probably accounted for by the diagnosis being made 
ante-partum and institution of appropriate treatment.
Adrenal pheochromocytoma accounted for the majority in this 
study (68.6%). Available reports are variable with some studies 
reporting high rates (78–92%)1,3,21,22,25 and only one study 
reporting a lower rate (61%) of adrenal tumours.23
Consistent with the available literature,3,22 benign tumours 
(77.1%) were far more common than malignant in our setting; 
however, the frequency of malignant pheochromocytoma 
28.6% (n = 10); histological features of both adrenal and extra-
adrenal tumours were documented in one patient (2.9%). Small 
nests (zellballen) of chromaffin-staining cells were the main 
histological manifestation of adrenal and extra-adrenal 
pheochromocytoma. Malignancy was diagnosed based on the 
presence of metastatic chromaffin tissue in the affected organs, 
namely lymph nodes (n = 5) and lung (n = 2) or by radiological 
documentation (CT/MRI/MIBG) of the metastasis (n = 1) to the 
liver and bone.
Table 3: Radiological characteristics in patients with 
pheochromocytoma at presentation (n = 35)
Notes: *CT = computerised tomography; MRI = magnetic resonance imaging; 
MIBG = meta-iodobenzylguanidine; PET = positron emission tomogram.
Factor Available data (n)  n  %
Radiological finding 
CT scan* 31 31 88.6
 Location
 Adrenal only 31 20 64.5
 Unilateral 31 18  90
 Bilateral 31 2  10
 Extra-adrenal only 31 10 32.3
 Combined adrenal/extra-adrenal 31 1  3.2
 Invasive tumours 31 3  9.7
 Associated necrosis, calcification 
or haemorrhage
31 4 12.9
MRI scan ⃰ 4 4 11.4
 Location
 Adrenal 4 4 100
 Unilateral 4 3  75
 Bilateral 4 1  25
 Extra-adrenal 4 0 0.0
 Invasive tumours 4 1  25
 Associated necrosis, calcification 
or haemorrhage
4 0 0.0
MIBG study* 21 21  60
 Location
 Adrenal only 21 11 52.4
 Unilateral 21 11  100
 Bilateral 21 0  0.0
 Extra-adrenal only 21 7 33.3
 Combined adrenal/extra-adrenal 21 1  4.8
 Unidentified tumours 21 2  9.5
 Invasive tumours 21 1  4.8
 Associated necrosis, calcification 
or haemorrhage
21 1  4.8
 PET scan* 9 9 25.7
 Location
 Adrenal 9 7 77.8
 Unilateral 9 7 77.8
 Bilateral 9 0  0.0
 Extra-adrenal 9 2 22.2
 Invasive tumours 9 0  0.0
 Associated necrosis, calcification 
or haemorrhage
9 0  0.0
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In the current study, 57.1% of patients were diagnosed based on 
biochemical results, much lower than that reported (88.8–96.5%) 
in other studies,3,6 and is probably accounted for by the low 
sensitivity and specificity of the tests used.
Similar to other studies,3,19,25 anatomical imaging (CT or MIBG 
scans) was able to correctly localise all tumours preoperatively. 
MIBG correctly identified the tumour in 90%; this is higher than 
that reported from a Chinese study (79%),19 but similar to other 
studies (88–98%),26–28 and may be related to large tumour sizes in 
this study.
An anterior midline surgical approach was used in just over half 
our patients (54.3%), in view of the fact that large tumours were 
identified with preoperative localisation. This is compatible with 
the study by Lo et al. 19 (mean tumour size 6.4 cm), but higher 
than in other studies (mean tumour size 4.8 cm).9,29,30
Tumour size in our study (6.4 cm) was larger than that recorded 
in other studies (mean 5.2 cm).3,4,7,8 This may be accounted for by 
the late presentation or delayed referral for specialised care. 
However, in concordance with other studies,19,25 malignant 
tumours (mean size 9  cm) were larger than benign (mean size 
5.6 cm).
In the present study, for patients with metastatic tumours, 
radiotherapy (11.4%) and chemotherapy (2.9%) were both used 
as adjunctive therapies and this is in keeping with the 10–21% 
reported for radiotherapy use,31,32 but lower than that for use of 
chemotherapy (16–30%).31,32
In the current study, 80% were deemed as cure (biochemically 
and/or radiologically) and is similar to results reported in other 
studies (79–92.6%).2,15,19,23
Available information on mortality rates is variable. The mortality 
of 5.9% found in this series is lower than that reported by 
Modigliani et al. (13%)20 whose results may be related to the high 
proportion of familial cases of pheochromocytoma (all patients 
had either MEN I2A or MEN I2B) in that study. By contrast, low 
mortality rates have also been reported in the Johannesburg 
study (7.4%).23
This study has several limitations including that it is a 
retrospective chart review in a single centre, the small number of 
patients and the biochemical tests used for diagnosis. However, 
the last report from this country was in 2011 from Johannesburg 
and this is the first from this centre, and may serve to highlight 
the late presentation and the need for a high index of suspicion 
at a primary health care level to facilitate early referral.
Conclusion
Patients presenting to IALCH had intra-abdominal tumours with 
high cure rates despite large tumour size. Mortality was low but 
there was a high rate of perioperative complications. The clinical 
presentation and large tumours probably relate to late 
presentation. A high index of suspicion at primary health care 
levels and a multidisciplinary approach is necessary to treat 
these rare tumours effectively. Large prospective studies are 
required to confirm the results of this study.
(22.9%) is higher than the 4–15% reported;15,20,23 and probably 
accounts for the high proportion of large tumours found in this 
study.
As in other studies,3,14,23 familial syndromes were diagnosed in 
the minority (n = 6; 17.1%). In our setting the frequency of 
patients with MEN2A is higher than that reported from 
Johannesburg (1.9%)23 but lower than that reported by Safwat et 
al. (14.9%),3 Lo et al. (10.4%)19 and Fernández-Calvet et al. (7.1%).22 
Unlike other studies where genetic tests were used to diagnose 
inherited cases,5,23 in this study familial tumours were diagnosed 
primarily on the basis of the positive family history of 
pheochromocytoma and presence of biochemical and 
radiological features of other components of inherited 
pheochromocytoma syndromes such as bilateral tumours, renal 
cell carcinoma, or medullary thyroid carcinoma. Selective genetic 
testing has only recently become available at our centre; only 
two of the six familial pheochromocytoma patients underwent 
genetic testing and no gene mutation was detected.
Table 4: Therapeutic modalities and perioperative complications in 
patients with pheochromocytoma (n = 35)
Factor Available data (n) n %
Mode of therapy
 Surgery 35 34 97.1
 Anterior midline approach 35 19 54.3
 Laparoscopic adrenalectomy 35 15 42.9
 Primary medical 35 1  2.9
 Additional treatment 35 4 14.3
 MIBG-based radiation 35 4 11.4
 Chemotherapy 35 1  2.9
Perioperative complication
 Hypotension 34 19 55.9
 Haemorrhage 34 7 20.6
 Hypertension 34 5 14.7
 Hypoglycaemia 34 0  0.0
 Arrhythmia 34 0  0.0
 Death 34 2  5.9
Table 5: Baseline biochemistry in cured (n = 28) and not-cured (n = 7) 
patients with pheochromocytoma*
Notes: Data are medians (IQR).
*Defined as biochemical cure in secretory tumours or radiological in non-
functional tumours.
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